Literature DB >> 1423943

Optimization of retroviral vector-mediated gene transfer into endothelial cells in vitro.

M L Kahn1, S W Lee, D A Dichek.   

Abstract

Retroviral vector-mediated gene transfer into endothelial cells is relatively inefficient with transduction rates as low as 1-2% in vitro and even lower in vivo. To increase the efficiency of gene transfer into endothelial cells, we used retroviral vectors expressing beta-galactosidase and urokinase and measured endothelial cell transduction efficiencies with quantitative assays for beta-galactosidase and urokinase protein. We evaluated several techniques reported to improve the efficiency of retroviral transduction in vitro, including 1) extended periods of exposure to vector, 2) repeated exposures to vector, 3) maximization of the ratio of vector particles to endothelial cells by increasing the volume and concentration of vector particles or by decreasing the number of endothelial cells exposed, 4) cocultivation of endothelial cells with vector-producing cells, and 5) variation of the type and concentration of polycation used with the retroviral vector. Only the use of more concentrated (higher titer) vector-containing supernatant and the use of the polycation DEAE-dextran improved the efficiency of gene transfer into endothelial cells in vitro. In an optimized transduction protocol, a 60-second exposure to 1 mg/ml DEAE-dextran followed by a single 6-hour exposure to supernatant of a titer of 10(5)-10(6) colony-forming units/ml resulted in transduction efficiencies of 50-90% with both vectors. Decreasing the time of the supernatant exposure to 15 minutes permitted transduction efficiencies of 15-20% while significantly minimizing the duration of the transduction. Therefore, the optimized protocol allows high efficiency in vitro gene transfer into endothelial cells within several hours. The briefer protocol may prove useful for in vivo gene transfer in which the time of exposure to the supernatant is limited.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423943     DOI: 10.1161/01.res.71.6.1508

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

2.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

3.  Proteoglycans secreted by packaging cell lines inhibit retrovirus infection.

Authors:  J M Le Doux; J R Morgan; R G Snow; M L Yarmush
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Retrovirus infection: effect of time and target cell number.

Authors:  J R Morgan; J M LeDoux; R G Snow; R G Tompkins; M L Yarmush
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 5.  Gene therapy for vascular diseases.

Authors:  K K Wu; P Zoldhelyi; J T Willerson; X M Xu; D S Loose-Mitchell; L H Wang
Journal:  Tex Heart Inst J       Date:  1994

6.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation.

Authors:  Peter Chen; Laura E Abacherli; Samuel T Nadler; Ying Wang; Qinglang Li; William C Parks
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

8.  Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection.

Authors:  S Andreadis; T Lavery; H E Davis; J M Le Doux; M L Yarmush; J R Morgan
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.